Search academic texts

Information × Registration Number 0216U005323, 0114U000061 , R & D reports Title Optimization of complex treatment of uterine sarcomas by determining the levels of tumor malignancy. popup.stage_title Head Sukhina О.M., Доктор медичних наук Registration Date 07-07-2016 Organization Grigor'ev Institut for Medical Radiology popup.description2 Object of study: combined treatment of uterine sarcomas. Objective: to increase the effectiveness of treatment of patients with uterine sarcomas by its individualization through a comprehensive evaluation of malignant potential tumors based on the immunohistochemical studies. Methods and apparatus: roentgenological, morphological, clinical, instrumental, statistical; universal dosimeter UNIDOS-Е. Theoretical and practical results: In this investigation was determined the significance of immunohistochemical markers depending on the histostructure of the tumor. In the absence of the marker Bcl 2 the recurrence of leiomyosarcoma was observed in 66.7 % of patients; in the absence of estrogen and progesterone receptors - in 80.0 % of cases; with a positive indicator of p53 protein expression - in 28.5 % of patients. At the same time 80.0 % of endometrial stromal sarcoma recurrence were observed in cases with a negative expression of estrogen and progesterone receptors. The expediency of radiotherapy in uterine sarcomas was substantiated, depending on their level and the histological forms of a tumor. It was proved that surgery and postoperative radiotherapy reduce the incidence of leiomyosarcoma manifestation in stage I-II against only surgery, especially when using intracavitary irradiation. There was no difference in terms of tumor progression in endometrial stromal sarcoma stage I-II, depending on the scheme. Novelty: was determined the significance of immunohistochemical markers p53, Ki-67, Bcl 2, ER, PR, etc., marker Bcl 2 and the presence of progesterone receptors are positive prognostic factors both in leiomyosarcoma and endometrial stromal sarcoma, especially with a negative expression of p53 protein. The effectiveness of implementation: exclusion of chemotherapy from a cancer patient's treatment plan results in a saving of medicines and money. Field of use: oncology, radiology. Product Description popup.authors Артамонова Н.О. Волошина Н.М. Довга О.В. Дригваль А.А. Кононенко О.К. Кругова І.М. Кульчаєва Т.В. Ланько Л.Г. Нестеренко А.С. Пащенко В.Б. Радченко О.А. Скрипник Л.Д. Сплюхина О.В. Сухін В.С. Сухіна О.М. popup.nrat_date 2020-04-02 Close